Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) – Unaudited Quarterly Results for Q1 FY2026

---

Introduction

Piramal Pharma Limited (the “Company”) filed a board‑approved unaudited financial statement for the three months ended 30 June 2026. The filing was submitted to both the BSE and NSE in compliance with SEBI Listing Regulations (Regulation 33 & 47).

---

Financial Highlights (Quarter ended 30 June 2026)

Metric (Rs. in Crores)	Q1 FY2026
Revenue from operations	1,124.95
Other income (net)	114.63
Total income	1,239.58
Cost of materials consumed	649.70
Purchases of stock‑in‑trade	234.64
Change in inventories of finished goods & stock‑in‑trade	(390.29)
Employee benefits expense	216.34
Finance costs	16.36
Depreciation & amortisation	65.73
Other expenses (net)	297.62
Total expenses	1,090.10
Profit before tax	149.48
Current tax (incl. prior year)	24.93
Deferred tax (net)	11.07
Total tax expense	36.00
Net profit after tax	113.48
Other Comprehensive Income (Loss), net of tax	(5.00)
Total comprehensive income	108.48
Basic EPS (Rs.)	0.85
Diluted EPS (Rs.)	0.85
Paid‑up equity share capital (Rs. 10 each)	1,327.35
Other equity	6,813.97

All figures are unaudited and presented on a standalone basis.

---

Board Approval & Regulatory Compliance

• Board meeting: 29 July 2026, 5:30 pm – 8:30 pm.
• The Board approved the unaudited standalone and consolidated financial results for Q1 FY2026.
• The Company will publish the results in newspapers as required under Regulation 47 of the SEBI Listing Regulations.
• The results are also available on the Company’s website: www.piramalpharma.com.

---

Auditor’s Limited Review

• Auditor: Suresh Surana & Associates LLP.
• Conducted a limited review in accordance with the Standard on Review Engagements (SRE) 2410, providing moderate assurance that the statement is free from material misstatement.
• The auditors concluded that no material misstatements were identified and that the statement complies with Regulation 33 requirements.

---

Additional Notes

• Exceptional items: None reported for the quarter ended 30 June 2026. (For the quarter and year ended 31 March 2026, exceptional items of Rs 92.51 crore were disclosed, but they do not affect Q1 FY2026 results.)
• Segment reporting: The Company operates in a single segment; therefore, segment disclosure is not applicable.
• Compliance statements: The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and the Companies Act, 2013.

---

The information above reflects only the data contained in the Company’s filing dated 29 July 2026.